Introduction & Objective: Continuous glucose monitors (CGM) help manage glycemic control, but severe hypoglycemic events (SHE) remain challenging for adults with T1D. SHE may also reduce health-related quality of life (HRQoL) and increase humanistic and economic burden. Published literature on HRQoL in adult CGM users with T1D is limited.

Methods: Adult (≥18 years) CGM users from the T1D Exchange Registry completed an online self-report survey with SHE experiences, impaired awareness of hypoglycemia (IAH, Modified Gold Score), and patient-reported outcome measures (PROM). SHE cohorts were created based on SHE frequency in the past 12 months and presence/absence of IAH: problematic SHE, single SHE/no IAH, undetermined IAH, and no SHE (defined in the Table). Descriptive results (mean, SD) of PROM are reported overall and by SHE cohort.

Results: Overall, participants (N=1,847) were 45.9 years old, had T1D for 29 years (SD 15.1), and reported 1.8 SHE (SD 13.3) in the past year. Variability in patient-reported burden and HRQoL impairment was observed across cohorts. The problematic SHE cohort reported the highest mean burden and impairment (Table).

Conclusion: Despite advanced diabetes technology utilization, individuals with T1D and SHE experience substantial negative impacts of HRQoL, highlighting the significant unmet need in this patient population.

graphic
View largeDownload slide
Disclosure

A. Boateng-Kuffour: Employee; Vertex Pharmaceuticals Incorporated. P. Callahan: Employee; Vertex Pharmaceuticals Incorporated. K. Chandarana: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated, Novo Nordisk, Eli Lilly and Company. D. Barry: Employee; Vertex Pharmaceuticals Incorporated. L. Chen: None. C.S. Kelly: None. H. Nguyen: None. K.S.M. Chapman: None. E.M. Cornelius: None. W. Wolf: None. W.H. Polonsky: Research Support; Abbott Diagnostics, Dexcom, Inc. Consultant; Eli Lilly and Company, Sanofi. Advisory Panel; embecta. Consultant; Vertex Pharmaceuticals Incorporated. Advisory Panel; 9am Health.

Funding

Vertex Pharmaceuticals Incorporated

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.